Cisplatin is known to provide durable disease control in metastatic urothelial cancer (mUC) patients compared to carboplatin. However, its underlying mechanism is poorly understood. A study was conducted on 851 mUC patients to explore whether the immunomodulatory effects of cisplatin are responsible for its beneficial outcomes. In the study, a combination of gemcitabine and cisplatin (GemCis) achieved improved outcomes (overall survival rate – 27.89 vs.
14.0 months) in patients with preexisting adaptive immunity compared to the combination of gemcitabine and carboplatin (GemCarbo). In addition, GemCis with atezolizumab induced transcriptional changes in circulating immune cells, increasing antigen presentation and T-cell activation programs. Furthermore, in vitro experiments confirmed that cisplatin exhibited direct immunomodulatory effects on cancer cells, inducing dendritic cell…
